QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

HOME  |   SEARCH  |   ARCHIVE  |   SUBSCRIBE  |   CONTACT  |   HELP

The Journal of Neuroscience, July 25, 2007, 27(30):8138-8148; doi:10.1523/JNEUROSCI.0319-07.2007

This Article Full Text Full Text (PDF) Submit an eLetter Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Related articles in J. Neurosci. Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (25) Citing Articles via Google Scholar Google Scholar Articles by Caudle, W. M. Articles by Miller, G. W. Search for Related Content PubMed PubMed Citation Articles by Caudle, W. M. Articles by Miller, G. W. Pubmed/NCBI databases Gene GEO Profiles HomoloGene UniGene Compound via MeSH Substance via MeSH Hazardous Substances DB DOPAMINE

 Previous Article  |  Next Article 

Neurobiology of Disease
Reduced Vesicular Storage of Dopamine Causes Progressive Nigrostriatal Neurodegeneration

W. Michael Caudle,^1,2 Jason R. Richardson,^1,2,3 Min Z. Wang,^1,2 Tonya N. Taylor,^1,2 Thomas S. Guillot,^1,2 Alison L. McCormack,⁴ Rebecca E. Colebrooke,⁵ Donato A. Di Monte,⁴ Piers C. Emson,⁵ and Gary W. Miller^1,2

¹Center for Neurodegenerative Disease, ²Department of Environmental and Occupational Health, Rollins School of Public Health, Emory University, Atlanta, Georgia 30322, ³Department of Environmental and Occupational Medicine, University of Medicine and Dentistry-New Jersey/Robert Wood Johnson Medical School and Environmental and Occupational Health Sciences Institute, Piscataway, New Jersey 08854, ⁴The Parkinson's Institute, Sunnyvale, California 94089, and ⁵The Babraham Institute, Neurobiology Programme, Babraham, Cambridge CB2 4AT, United Kingdom

Correspondence should be addressed to Gary W. Miller, Center for Neurodegenerative Disease, Emory University, Whitehead Biomedical Research Building, Room 505K, 615 Michael Street, Atlanta, GA 30322. Email: gary.miller{at}emory.edu

The vesicular monoamine transporter 2 (VMAT2; SLC18A2) is responsible for packaging dopamine into vesicles for subsequent release and has been suggested to serve a neuroprotective role in the dopamine system. Here, we show that mice that express 5% of normal VMAT2 (VMAT2 LO) display age-associated nigrostriatal dopamine dysfunction that ultimately results in neurodegeneration. Elevated cysteinyl adducts to L-DOPA and DOPAC are seen early and are followed by increased striatal protein carbonyl and 3-nitrotyrosine formation. These changes were associated with decreased striatal dopamine and decreased expression of the dopamine transporter and tyrosine hydroxylase. Furthermore, we observed an increase in -synuclein immunoreactivity and accumulation and neurodegeneration in the substantia nigra pars compacta in aged VMAT2 LO mice. Thus, VMAT2 LO animals display nigrostriatal degeneration that begins in the terminal fields and progresses to eventual loss of the cell bodies, -synuclein accumulation, and an L-DOPA responsive behavioral deficit, replicating many of the key aspects of Parkinson's disease. These data suggest that mishandling of dopamine via reduced VMAT2 expression is, in and of itself, sufficient to cause dopamine-mediated toxicity and neurodegeneration in the nigrostriatal dopamine system. In addition, the altered dopamine homeostasis resulting from reduced VMAT2 function may be conducive to pathogenic mechanisms induced by genetic or environmental factors thought to be involved in Parkinson's disease.

Key words: Parkinson's disease; vesicular monoamine transporter 2; dopamine; neurodegeneration; dopamine transporter; tyrosine hydroxylase

---

Received Jan. 24, 2007; revised May 25, 2007; accepted June 21, 2007.

Correspondence should be addressed to Gary W. Miller, Center for Neurodegenerative Disease, Emory University, Whitehead Biomedical Research Building, Room 505K, 615 Michael Street, Atlanta, GA 30322. Email: gary.miller{at}emory.edu

Related articles in J. Neurosci.:

This Week in The Journal

J. Neurosci. 2007 27: i. [Full Text]  

This article has been cited by other articles:

				T. N. Taylor, W. M. Caudle, K. R. Shepherd, A. Noorian, C. R. Jackson, P. M. Iuvone, D. Weinshenker, J. G. Greene, and G. W. Miller Nonmotor Symptoms of Parkinson's Disease Revealed in an Animal Model with Reduced Monoamine Storage Capacity J. Neurosci., June 24, 2009; 29(25): 8103 - 8113. [Abstract] [Full Text] [PDF]

				X.-H. Lu, S. M. Fleming, B. Meurers, L. C. Ackerson, F. Mortazavi, V. Lo, D. Hernandez, D. Sulzer, G. R. Jackson, N. T. Maidment, et al. Bacterial Artificial Chromosome Transgenic Mice Expressing a Truncated Mutant Parkin Exhibit Age-Dependent Hypokinetic Motor Deficits, Dopaminergic Neuron Degeneration, and Accumulation of Proteinase K-Resistant {alpha}-Synuclein J. Neurosci., February 18, 2009; 29(7): 1962 - 1976. [Abstract] [Full Text] [PDF]

				X. Hu, D. Zhang, H. Pang, W. M. Caudle, Y. Li, H. Gao, Y. Liu, L. Qian, B. Wilson, D. A. Di Monte, et al. Macrophage Antigen Complex-1 Mediates Reactive Microgliosis and Progressive Dopaminergic Neurodegeneration in the MPTP Model of Parkinson's Disease J. Immunol., November 15, 2008; 181(10): 7194 - 7204. [Abstract] [Full Text] [PDF]

				S. Hamamichi, R. N. Rivas, A. L. Knight, S. Cao, K. A. Caldwell, and G. A. Caldwell Hypothesis-based RNAi screening identifies neuroprotective genes in a Parkinson's disease model PNAS, January 15, 2008; 105(2): 728 - 733. [Abstract] [Full Text] [PDF]

				L. Chen, Y. Ding, B. Cagniard, A. D. Van Laar, A. Mortimer, W. Chi, T. G. Hastings, U. J. Kang, and X. Zhuang Unregulated Cytosolic Dopamine Causes Neurodegeneration Associated with Oxidative Stress in Mice J. Neurosci., January 9, 2008; 28(2): 425 - 433. [Abstract] [Full Text] [PDF]

				A. D. Gitler, B. J. Bevis, J. Shorter, K. E. Strathearn, S. Hamamichi, L. J. Su, K. A. Caldwell, G. A. Caldwell, J.-C. Rochet, J. M. McCaffery, et al. The Parkinson's disease protein {alpha}-synuclein disrupts cellular Rab homeostasis PNAS, January 8, 2008; 105(1): 145 - 150. [Abstract] [Full Text] [PDF]

				J. R. Mazzulli, M. Armakola, M. Dumoulin, I. Parastatidis, and H. Ischiropoulos Cellular Oligomerization of {alpha}-Synuclein Is Determined by the Interaction of Oxidized Catechols with a C-terminal Sequence J. Biol. Chem., October 26, 2007; 282(43): 31621 - 31630. [Abstract] [Full Text] [PDF]

Home  |   Search  |   Archive  |   Subscribe  |   Contact  |   Help